Spexin

Spexin was uncovered not by classical purification but by a bioinformatic search for hidden peptide hormones, and subsequent work placed it within an evolutionary family alongside galanin and kisspeptin. Genomic and syntenic analysis showed that spexin, galanin, and kisspeptin genes arose from local duplications before the vertebrate whole-genome duplications, and a ligand-receptor study demonstrated that spexin activates the GALR2 and GALR3 family receptors, but not GALR1, with notably higher potency at GALR3 than galanin itself ^[1]. This makes spexin a natural GALR2/GALR3 ligand and a key to understanding galanin-family signaling.

Metabolically, spexin behaves as a regulatory adipokine. In a study of children, circulating spexin was significantly lower in those with obesity than in normal-weight peers, the highest tertile of spexin was independently protective against obesity, and spexin levels correlated with interleukin markers, fasting insulin, and insulin resistance, implicating the peptide in energy balance, glucose metabolism, and inflammation ^[2]. These associations have positioned spexin as a candidate biomarker and modulator in obesity and metabolic disease, complementing animal work showing effects on food intake and body weight.

Spexin also has clear peripheral actions. In mice, serum spexin was reduced in functional constipation and in fasting, and spexin injection accelerated intestinal and colonic transit while stimulating smooth-muscle contraction; this prokinetic effect was blocked by the GALR2 antagonist M871 but not by a GALR3 antagonist, and depended on extracellular calcium entry through L-type voltage-dependent calcium channels, pinning the gut-motility action specifically on GALR2 ^[3]. Additional research links spexin to cardiovascular regulation, reproduction, anxiety, and nociception. Spexin remains an endogenous peptide under active investigation rather than an approved therapeutic, though its metabolic profile has generated interest in weight and glucose applications.

Spexin is an endogenous peptide, and human data are largely observational rather than interventional, so a formal safety profile for exogenous administration is not established. Because it influences gut motility, appetite, glucose handling, and cardiovascular function, supraphysiologic dosing could plausibly affect digestion, metabolism, and blood pressure. No standardized human dosing, pharmacokinetics, or toxicology exist, and it should be regarded as a research peptide despite commercial interest in its metabolic associations.

Spexin was predicted computationally in 2007 through a bioinformatic hunt for uncharacterized peptide hormones, then validated experimentally. In 2014 Kim and colleagues placed it evolutionarily within the spexin, galanin, and kisspeptin family and identified it as a GALR2/GALR3 ligand. Subsequent work across metabolic, gastrointestinal, cardiovascular, and reproductive fields, including clinical association studies in obesity, expanded its physiological portfolio and elevated its profile as a candidate metabolic regulator.

Spexin is increasingly recognized in endocrinology and metabolic research as an important, if still emerging, regulatory peptide, frequently discussed as a biomarker inversely related to obesity and insulin resistance. Its identity as a natural galanin-receptor ligand has made it central to galanin-family pharmacology. In consumer and nootropic markets it is comparatively obscure, though its metabolic associations attract periodic interest. It is not an approved therapeutic.